|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| Endometriosis Pipeline Forecast |
|
|
|
|
€ 6 080,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Mars 2005 |
Taille du document : |
N/A |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
ePharmacies: Strategic Implications for the Healthcare Industry
230 pages | Mars 2000 |
Increasingly, the pharmaceutical sector is being influenced by the Internet.Are you in a position to:- Predict future shifts in drug prescribing and purchasing behavior?- Anticipate consolidation in b |
955,00 €
|
| |
| |
The Global Parallel Trade Outlook 2001 - 2006: A Country-by-Country Analysis
188 pages | Septembre 2001 |
Global Parallel Trade Outlook 2001: A country-by-country analysis, a new report by Reuters Business Insight, provides a detailed update on the status of parallel trade in the global marketplace.
1 200,00 €
|
|
| |
| |
Pharmaceutical Pricing Strategies 2000: Entering the new millennium
240 pages | Juin 2000 |
The favorable climate of the pharmaceutical sector has changed radically over the past ten years.
Where once a company's freedom over pricing decisions was almost limitless, external pressure |
955,00 €
|
| |
| |
Pharmaceutical Packaging: UK
90 pages | Avril 2000 |
· Analyse the changes in demand for pharmaceutical packaging in the UK, over the next 5 years
· Understand the main factors affecting demand
· Examine the struct |
1 249,31 €
|
| |
| |
Healthcare In Wales
50 pages | Mai 2000 |
The Welsh Presentation Includes:- The Structure Of The NHS In Wales- Revenue Expenditure On Health Services In Wales- Number Of Hospital Units - Number Of Available Inpatient Beds- Number Of Occupied |
327,00 €
|
| |
| |
The Evolution of DTC marketing across key pharmaceutical markets
152 pages | Mars 2000 |
Pharmaceutical companies mainly market their products through contact between their sales force and heathcare providers.
However, due to the nature of its products, the pharmaceutical industry |
955,00 €
|
| |
| |
Strategic Intelligence: The Top 12 Pharmaceutical Companies
158 pages | Novembre 2001 |
The pressure on the pharmaceutical company R&D has never been greater.
It is estimated that $100 billion worth of products will face patent expiry by 2005.
Of this, $37 billion represe |
1 021,89 €
|
| |
| |
The Pharmaceutical industry in the 21st Century
150 pages | Octobre 1998 |
Does the 21st century herald the beginning of a genomics revolution? Which disease areas will provide the greatest growth potential and why? Which technologies have the greatest potential to max |
795,00 €
|
| |
| |
The Drug Delivery Outlook to 2005
150 pages | Février 1999 |
Strategic overview : defines and values the market covered in the report, provides a macro analysis of the reasons why the drug delivery sector is growing at current rates and predicts how the c |
795,00 €
|
| |
| |
Regulatory Affairs: Paths to Approval
113 pages | Février 1999 |
Area Specific Chapters : The regulatory systems governing clinical trials and drug approvals are examined for the US, Europe, and Australia, Canada and Japan, including analysis of the implicatio |
795,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Endometriosis Pipeline Forecast |
|
|
Introduction
Endometriosis is treated with a number of drug classes, including hormonal contraceptives, progestogens and GnRH agonists, which are also used in other indications. Datamonitor's endometriosis forecast incorporates IMS diagnosis and MIDAS sales data into our in-house forecasting model to give a disease specific forecast that sees market growth from $1.31 billion in 2003 to $1.85 billion by 2014.
Reasons to Purchase
Support your commercial planning on accurate, endometriosis-specific market data by excluding product sales for indications other than endometriosis
Identify key competitors in local markets and target those with the potential for investment and development
Evaluate the potential of new drugs in development and in impact of key patent expiries on the market
|
|
|
PPLSEN
|
|
|
|
|
